STAT Plus Amicus Therapeutics said its drug for Pompe disease appeared to benefit patients with the disease in a small trial a modest but noteworthy milestone. httpsbuff.ly2HSxDTuÂ

STAT Plus: Amicus Therapeutics said its drug for Pompe disease appeared to benefit patients with the disease in a small trial, a modest but noteworthy milestone. https://buff.ly/2HSxDTu

17:00 EST 5 Feb 2019 | STAT

STAT Plus: Amicus Therapeutics said its drug for Pompe disease appeared to benefit patients with the disease in a small trial, a modest but noteworthy milestone. https://buff.ly/2HSxDTu

More From BioPortfolio on "STAT Plus: Amicus Therapeutics said its drug for Pompe disease appeared to benefit patients with the disease in a small trial, a modest but noteworthy milestone. https://buff.ly/2HSxDTu "